2023
10th World ADC Awards
Winner – LegoChem Biosciences
Runner-Up – Catalent SMARTag Technology
Winner – NJ Bio, Inc. & Charles River Laboratories
Winner – WuXi XDC
Runner-Up – Lonza, BSP Pharmaceuticals
Winner – Exelixis
Runner-Up – Duality Biologics
Winner – Enfortumab vedotin (PADCEV) – Seagen/Astellas
Runner-Up – BL-B01D1 – SystImmune, Patritumab deruxtecan - Daiichi Sankyo
Winner - Discovery of BT8009: A Nectin-4 - Targeting Bicycle Toxin Conjugate for the Treatment of Cancer
Runner-Up - Targeting LRRC15 Inhibits Metastatic Dissemination of Ovarian Cancer
Winner - Trastuzumab deruxtecan in Previously Treated HER2-Positive Breast Cancer
Runner-Up- Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer
N-Myristoyltransferase (NMT) inhibitors as completely novel payloads for Antibody Drug Conjugates, deliver extensive tumor regression at well tolerated doses, Myricx Bio
Nathan Tumey, Binghampton University
Dr. Shanu Modi, Memorial Sloan Kettering Cancer Center
Puja Sapra
2022
9th World ADC Awards
Winner – Synaffix
Runner-Up – Catalent SMARTag Technology
Winner – NJ Bio
Runner-Up – Abzena
Winner – BSP Pharmaceuticals
Runner-Up – WuXi XDC
Winner – Iksuda Therapeutics
Runner-Up – Exelixis
Winner – Mirvetuximab soravtansine, ImmunoGen
Runner-Up – Patritumab deruxtecan, Daiichi Sankyo
Winner - Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance. Yamazaki CM, Yamaguchi A, Anami Y, Xiong W, Otani Y, Lee J, Ueno NT, Zhang N, An Z, Tsuchikama K. Nat Commun. 2021 Jun 10;12(1):3528. doi: 10.1038/s41467-021-23793-7. PMID: 34112795
Runner-Up - The B7-H3-Targeting Antibody-Drug Conjugate m276-SL-PBD Is Potently Effective Against Pediatric Cancer Preclinical Solid Tumor Models. Kendsersky NM, Lindsay J, Kolb EA, Smith MA, Teicher BA, Erickson SW, Earley EJ, Mosse YP, Martinez D, Pogoriler J, Krytska K, Patel K, Groff D, Tsang M, Ghilu S, Wang Y, Seaman S, Feng Y, Croix BS, Gorlick R, Kurmasheva R, Houghton PJ, Maris JM. Clin Cancer Res. 2021 May 15;27(10):2938-2946. doi: 10.1158/1078-0432.CCR-20-4221. Epub 2021 Feb 22. PMID: 33619171
Winner - Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, Brufsky A, Sardesai SD, Kalinsky K, Zelnak AB, Weaver R, Traina T, Dalenc F, Aftimos P, Lynce F, Diab S, Cortés J, O'Shaughnessy J, Diéras V, Ferrario C, Schmid P, Carey LA, Gianni L, Piccart MJ, Loibl S, Goldenberg DM, Hong Q, Olivo MS, Itri LM, Rugo HS; ASCENT Clinical Trial Investigators. N Engl J Med. 2021 Apr 22;384(16):1529-1541. doi: 10.1056/NEJMoa2028485. PMID: 33882206 Clinical Trial.
Runner-Up - Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. Caimi PF, Ai W, Alderuccio JP, Ardeshna KM, Hamadani M, Hess B, Kahl BS, Radford J, Solh M, Stathis A, Zinzani PL, Havenith K, Feingold J, He S, Qin Y, Ungar D, Zhang X, Carlo-Stella C.Lancet Oncol. 2021 Jun;22(6):790-800. doi: 10.1016/S1470-2045(21)00139-X. Epub 2021 May 11. PMID: 33989558 Clinical Trial.
GLK-33, novel anti-CD33 ADC with auristatin payload MMAU shows wide preclinical therapeutic window, and, Hydrophilic glycopeptide linker improves properties of auristatin, anthracycline and exatecan ADCs, Glykos
Dhaval Shah, University at Buffalo, The State University of New York
Gilles Gallant, Daiichi Sankyo
Robert Lutz, Iksuda Therapeutics
2021
8th World ADC Awards
Winner: Legochem biosciences
Runner Up: Synaffix
Winner: Silverback Therapeutics
Runner Up: Macrogenics
This year was competition was tight for most promising clinical candidate. So much so that we had two runners up:
Winner: patritumab deruxtecan (HER3-DXd; formerly U3-1402
The first runner up is; STRO-002 from Sutro Bio
The second runner up: Trastuzumab duocarmazine (SYD985)
Winner: Lonza
Runner up: BSP Pharmaceuticals
Winner: NJ Bio
Runner up: Sterling Pharma Solutions
Winner: A bi-orthogonal system reveals antitumour immune function of pyroptosis.
Pyrop-tyosis
Wang Q, Wang Y, Ding J, Wang C, Zhou X, Gao W, Huang H, Shao F, Liu Z.Nature. 2020 Mar;579(7799):421-426. doi: 10.1038/s41586-020-2079-1. Epub 2020 Mar 11.PMID: 32188939
Citations: 106
Runner Up: Antibody-PROTAC Conjugates Enable HER2-Dependent Targeted Protein Degradation of BRD4.
Maneiro MA, Forte N, Shchepinova MM, Kounde CS, Chudasama V, Baker JR, Tate EW.ACS Chem Biol. 2020 Jun 19;15(6):1306-1312. doi: 10.1021/acschembio.0c00285. Epub 2020 Apr 30.PMID: 32338867
Citations: 30
Winner: Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.
Modi S, Saura C, Yamashita T, Park YH, Kim SB, Tamura K, Andre F, Iwata H, Ito Y, Tsurutani J, Sohn J, Denduluri N, Perrin C, Aogi K, Tokunaga E, Im SA, Lee KS, Hurvitz SA, Cortes J, Lee C, Chen S, Zhang L, Shahidi J, Yver A, Krop I; DESTINY-Breast01 Investigators.N Engl J Med. 2020 Feb 13;382(7):610-621. doi: 10.1056/NEJMoa1914510. Epub 2019 Dec 11.PMID: 31825192
Citations: 456
Runner Up: Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Sehn LH, Herrera AF, Flowers CR, Kamdar MK, McMillan A, Hertzberg M, Assouline S, Kim TM, Kim WS, Ozcan M, Hirata J, Penuel E, Paulson JN, Cheng J, Ku G, Matasar MJ.J Clin Oncol. 2020 Jan 10;38(2):155-165. doi: 10.1200/JCO.19.00172. Epub 2019 Nov 6.PMID: 31693429
Citations: 206
Kyoji Tsuchikama, Associate Professor, University of Texas
GlycoConnect™ ADCs Based on Topoisomerase 1 Inhibitor Exatecan (SYNtecan™) Show Excellent In Vivo Efficacy and Tolerability - Synaffix
Philip Howard, Chief Scientific Officer, Spirogen
Greg Thurber, Associate Professor, Univ. of Michigan
2020
7th World ADC Awards
Synaffix – Winner
Legochem Bio – Runner Up
Sutro Biopharma – Winner
Mersana Therapeutics – Runner Up
Datopotamab deruxtecan; DS-1062 (Daiichi Sankyo) – Winner
Loncastuximab Tesirine (ADC Therapeutics) – Runner Up
Piramal – Winner
BSP Pharmaceuticals – Runner Up
Abzena – Winner
NJ Biopharmaceuticals – Runner Up
Winner:
Czechowicz A, Palchaudhuri R, Scheck A, Hu Y, Hoggatt J, Saez B, Pang WW, Mansour MK, Tate TA, Chan YY, Walck E, Wernig G, Shizuru JA, Winau F, Scadden DT, Rossi DJ. Selective hematopoietic stem cell ablation using CD117-antibody-drug-conjugates enables safe and effective transplantation with immunity preservation. Nat Commun. 2019 Feb 6;10(1):617. doi: 10.1038/s41467-018-08201-x. PMID: 30728354; PMCID: PMC6365495.
Runner Up:
Yamada K, Shikida N, Shimbo K, Ito Y, Khedri Z, Matsuda Y, Mendelsohn BA. AJICAP: Affinity Peptide Mediated Regiodivergent Functionalization of Native Antibodies. Angew Chem Int Ed Engl. 2019 Apr 16;58(17):5592-5597. doi: 10.1002/anie.201814215. Epub 2019 Mar 29. PMID: 30854738
Winner
von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, Wolmark N, Rastogi P, Schneeweiss A, Redondo A, Fischer HH, Jacot W, Conlin AK, Arce-Salinas C, Wapnir IL, Jackisch C, DiGiovanna MP, Fasching PA, Crown JP, Wülfing P, Shao Z, Rota Caremoli E, Wu H, Lam LH, Tesarowski D, Smitt M, Douthwaite H, Singel SM, Geyer CE Jr; KATHERINE Investigators. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. N Engl J Med. 2019 Feb 14;380(7):617-628. doi: 10.1056/NEJMoa1814017. Epub 2018 Dec 5. PMID: 30516102.
Aldo Braca, President & Founder, BSP Pharmaceuticals
Rakesh Dixit, President & CEO, BioNavigen
2019
6th World ADC Awards
Zymeworks (ZymeLink) – Winner
LegoChem Bio (Scaffold Based Approach) – Runner Up
ADC Therapeutics – Winner
Zymeworks – Runner Up
Trastuzumab Deruxtecan (DS-8201a) – Winner
Enfortumab Vedotin (Seattle Genetics/Astellas) – Runner Up
BSP Pharmaceuticals – Winner
Millipore Sigma – Runner Up
PPD – Winner
Abzena – Runner Up
Winner:
Rahul Palchaudhuri from Magenta Therapeutics with his poster on the half-life of their Amanitin Antibody Drug Conjugates.
Runner Up:
Richard Bethell at BiVictrix with their paper on Bispecific Antibody Drug Conjugates for the Treatment of Acute Myeloid Leukemia.
Winner:
Chemically triggered drug release from an antibody-drug conjugate leads to potent antitumour activity in mice. Rossin R, Versteegen RM, Wu J, Khasanov A, Wessels HJ, Steenbergen EJ, Ten Hoeve W, Janssen HM, van Onzen AHAM, Hudson PJ, Robillard MS. Nat Commun. 2018 May 4;9(1):1484.
Runner Up:
Chemically Defined Antibody- and Small Molecule-Drug Conjugates for in Vivo Tumor Targeting Applications: A Comparative Analysis. Cazzamalli S, Dal Corso A, Widmayer F, Neri D. J Am Chem Soc. 2018 Feb 7;140(5):1617-1621.
Winner:
Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma. Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A, Younes A, Alekseev S, Illés Á, Picardi M, Lech-Maranda E, Oki Y, Feldman T, Smolewski P, Savage KJ, Bartlett NL, Walewski J, Chen R, Ramchandren R, Zinzani PL, Cunningham D, Rosta A, Josephson NC, Song E, Sachs J, Liu R, Jolin HA, Huebner D, Radford J; ECHELON-1 Study Group. N Engl J Med. 2018 Jan 25;378(4):331-344. doi: 10.1056/NEJMoa1708984.
Dario Neri (ETH Zurich)
Alain Beck (Pierre Fabre)
2018 & Older
5th World ADC Awards
Sutro Biopharma (nnAA Conjugation) -WINNER
LegoChem Bio (Scaffold Based Approach) – Runner Up
Bicycle Therapeutics- WINNER
Sutro Biopharma-Runner Up
Polatuzumab Vedotin- WINNER
Sacituzumab Govitecan (IMMU-132)-Runner Up
BSP Pharmaceuticals- WINNER
Novasep-Runner Up
Charles River- WINNER
Abzena-Runner Up
Rovalpituzumab tesirine, a DLL3-targeted antibody-drugconjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study. Rudin CM, Pietanza MC, Bauer TM, Ready N, Morgensztern D, Glisson BS, Byers LA, Johnson ML, Burris HA 3rd, Robert F, Han TH, Bheddah S, Theiss N, Watson S, Mathur D, Vennapusa B, Zayed H, Lally S, Strickland DK, Govindan R, Dylla SJ, Peng SL, Spigel DR; SCRX16-001 investigators. Lancet Oncol. 2017 Jan;18(1):42-51.- WINNER
Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study. Perez EA, Barrios C, Eiermann W, Toi M, Im YH, Conte P, Martin M, Pienkowski T, Pivot X, Burris H 3rd, Petersen JA, Stanzel S, Strasak A, Patre M, Ellis P. J Clin Oncol. 2017 Jan 10;35(2):141-148.-Runner Up
Philipp Mueller, Boehringer Ingelheim -WINNER
Dr Ravi Chari, ImmunoGen - WINNER
- Best ADC Platform Technology
Winner - Bicycle Therapeutics
Runner-Up -SynAffix - Most Promising Clinical Candidate
Winner - Immunogen (Mirvetuximab soravtansine)
Runner-Up - Stemcentrx (Rova-T) - Best Contract Manufacturing (CMO) Provider
Winner - Lonza
Runner-up - BSP Pharmaceuticals - Best New Drug Developer
Winner - Mersana Therapeutics
Runner-Up - Heidelberg Pharma
- Best Contract Research (CRO) Provider
Winner - PPD
Runner-Up - SynGene - Best Publication 2016
Winner - A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy
Li JY, Perry SR, Muniz-Medina V, Wang X, Wetzel LK, Rebelatto MC, Hinrichs MJ, et al.
Cancer Cell 2016Runner-Up - Targeted drug delivery through the traceless release of tertiary and heteroaryl amines from antibody–drug conjugates
Staben LR, Koenig SG, Lehar SM, Vandlen R, Zhang D, Chuh J, Yu SF, et al
Nature Chemistry, 2016 - Individual Input to the Field
Gregory Winter - Long-Standing Contribution
Jagat Reddy Junutula
- Best ADC Platform Technology
Winner – Genentech (THIOMAB)
Runner Up – Sutro Biopharma (nnAA) - Best New Drug Developer
Winner – Stemcentrx
Runner Up – ADC Therapeutics - Most Promising Clinical Candidate
Winner – Seattle Genetics (SGN-CD33A)
Runner Up – Immunomedics (Sacituzumab Govitecan) - Best Contract Service Provider
Winner – BSP Pharmaceuticals (CMO)
Runner Up – Piramal (CMO) - Best Publication 2010-2014
Winner - Shen et al. Conjugation site modulates the in vivostability and therapeutic activity of antibody-drug conjugates
Nature Biotech 2012
Runner Up - Lyon et al. Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugates
Nature Biotech 2014 - Individual Input to the Field 2014/2015
Winner – Hans Peter Gerber (Pfizer)
Runner Up – Patrick van Berkel (ADC Therapeutics)
- Best ADC Platform Technology
Winner – Fleximer (Mersana Therapeutics)
Runner Up – Bicycles (Bicycle Therapeutics) - Most Promising Clinical Candidate
Winner – Rovalpituzumab tesirine (Abbvie-Stemcentrx)
Runner Up – MEDI4276 (MedImmune) - Best Contract Manufacturing (CMO) Provider
Winner - BSP Pharmaceuticals
Runner Up - Piramal - Best Contract Research (CRO) Provider
Winner - Abzena - Best New Drug Developer sponsored by Pfizer
Winner - ADC Therapeutics
Runner Up – Mersana Therapeutics - Best Publication 2015
Winner - Saunders et al., A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo. Sci Transl Med., 2015.
Runner Up - van Geel et al., Chemoenzymatic Conjugation of Toxic Payloads to the Globally Conserved N-Glycan of Native mAbs Provides Homogeneous and Highly Efficacious Antibody−Drug Conjugates; Bioconj. Chem., 2015. - Best Poster sponsored by Abbvie
Winner - Computational Exploration of Mechanistic Determinants of ADC Pharmacokinetics Using QSP Modeling Strategies; AK Wilkens et al.
Runner Up - Discovery and Characterization of ADCs with a Novel Mode of Action; G Piizzi et al. - Individual Input to the Field 2015/2016
Winner - David Thurston
Runner Up - Scott Dylla - Long-Standing Contribution
Winner - John Lambert
- Most Promising Drug Candidate
Winner: IMGN289 (ImmunoGen)
Runner Up: Polatuzumab Vedotin (Genentech)
- Best Scientific Innovation
Winner: PBD (Spirogen)
Runner Up: None
- Best Contract Service Provider
Winner: Piramal
Runner up: Lonza - Best Team:
Winner: Lonza Bioconjugates Team
Runner Up: ImmunoGen Scientific Leadership
Runner Up: Peter Senter’s Chemistry Group - Individual Input to Field (2013/2014):
Winner: Chris Martin
Runner up: John Lambert - Long-Standing Contribution to the Field:
Winner: Peter Senter
Runner Up: Ravi Chari